Last reviewed · How we verify
standard anti-tuberculosis agents
standard anti-tuberculosis agents is a Small molecule drug developed by National Taiwan University Hospital. It is currently in Phase 1 development.
At a glance
| Generic name | standard anti-tuberculosis agents |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Upper respiratory tract infection
- Nasopharyngitis
- Urinary tract infection
- Arthralgia
- Eosinophilia
- Dental caries
- Vomiting
- Pyrexia
- Hyperuricaemia
- Myalgia
- Dizziness
Key clinical trials
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women (PHASE1)
- ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD) (PHASE2)
- Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis (PHASE2)
- Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting (NA)
- PanACEA - STEP2C -01 (PHASE2)
- Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis (PHASE2)
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- standard anti-tuberculosis agents CI brief — competitive landscape report
- standard anti-tuberculosis agents updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI
Frequently asked questions about standard anti-tuberculosis agents
What is standard anti-tuberculosis agents?
standard anti-tuberculosis agents is a Small molecule drug developed by National Taiwan University Hospital.
Who makes standard anti-tuberculosis agents?
standard anti-tuberculosis agents is developed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).
What development phase is standard anti-tuberculosis agents in?
standard anti-tuberculosis agents is in Phase 1.
What are the side effects of standard anti-tuberculosis agents?
Common side effects of standard anti-tuberculosis agents include Headache, Upper respiratory tract infection, Nasopharyngitis, Urinary tract infection, Arthralgia, Eosinophilia.